Freyr Solutions

Freyr Solutions

Veranstaltungen

Suche

CCDS Development for Investigational Products

The complexity of global drug development continues to increase as pharmaceutical companies conduct multi-regional clinical trials, pursue simultaneous market authorizations, and navigate evolving Regulatory requirements across multiple jurisdictions. According to industry estimates, more than 50% of clinical development programs today involve multiple countries, requiring organizations to...

Freyr Solutions

2026-07-17 06:28:48

Digital Labeling Readiness

The pharmaceutical industry is undergoing a significant transformation in how product information is created, managed, and delivered. Regulatory authorities worldwide are increasingly exploring digital labeling initiatives to improve accessibility, enhance patient engagement, and enable faster dissemination of approved product information. From electronic Product Information (ePI) programs in...

Freyr Solutions

2026-07-17 06:27:19

What is a Biowaiver under JFDA Guidelines

A biowaiver under the Jordan Food and Drug Administration (JFDA) guidelines is a Regulatory approval that allows a pharmaceutical manufacturer to skip in vivo bioequivalence (BE) studies in human volunteers. Instead of testing the drug in humans to prove it performs the same as the innovator (reference) product, the JFDA allows the use of comparative in vitro dissolution testing as an...

Freyr Solutions

2026-06-30 13:22:20

What Is the 60-Day Silent Approval Mechanism for Clinical Trials in China

China has become a major destination for global clinical development, and one reason is its 60-day silent approval mechanism for clinical trials. Introduced as part of China’s drug Regulatory reforms and outlined under the National Medical Products Administration (NMPA) framework, this mechanism allows sponsors to begin clinical trials if regulators do not raise objections within 60...

Freyr Solutions

2026-06-30 13:21:03

Top 5 Pitfalls When Registering Medicines in Australia

Market Context Australia remains a highly attractive pharmaceutical market due to its strong regulatory framework and global credibility. However, registering medicinal products with the Therapeutic Goods Administration (TGA) requires more than just dossier submission. In 2026, sponsors are facing increasing scrutiny around submission quality, GMP compliance, and lifecycle...

Freyr Solutions

2026-06-30 13:19:34

Global Drug Registration 2026: Comparing TGA, FDA & EMA Regulatory Pathways

Market Context As pharmaceutical companies expand globally, understanding regional regulatory pathways has become essential for faster market access and lifecycle efficiency. In 2026, sponsors seeking approvals across Australia, the US, and Europe must navigate the distinct requirements of the Therapeutic Goods Administration (TGA), U.S. Food and Drug Administration (FDA), and European...

Freyr Solutions

2026-06-30 13:17:10

Japan Drug Approval Timelines

For pharmaceutical companies planning global launches, understanding drug approval timelines across regions is critical. While Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is aligned with global standards through ICH, approval timelines in Japan can differ significantly from those of the FDA (US) and EMA (EU). How Do PMDA Timelines Compare? In general: FDA is often...

Freyr Solutions

2026-06-30 13:13:36

China Pharma Trade & Market Access Trends

China continues to strengthen its position as a global pharmaceutical manufacturing, biotechnology, and healthcare innovation hub. Evolving trade agreements, Regulatory reforms, and supply chain strategies are creating new opportunities and challenges for global pharmaceutical companies seeking market entry and expansion in China. As pharmaceutical supply chains become increasingly globalized,...

Freyr Solutions

2026-06-30 13:10:07

Innovative Drug Development in China | NMPA Guide

China’s pharmaceutical landscape is rapidly evolving, making the country one of the most strategic destinations for innovative drug development, biotechnology investments, and pharmaceutical market expansion. With continuous National Medical Products Administration (NMPA) reforms, accelerated approval pathways, and increased focus on innovative therapies, global pharmaceutical and biotech...

Freyr Solutions

2026-06-30 13:08:56

China eCTD Compliance & NMPA Submission Guide

As China continues modernizing its pharmaceutical Regulatory systems, eCTD compliance has become increasingly important for pharmaceutical companies seeking successful NMPA submissions and faster Regulatory approvals. Organizations preparing China Regulatory submissions must ensure their dossiers meet evolving technical, operational, and compliance expectations. Why China eCTD Compliance...

Freyr Solutions

2026-06-30 13:08:02

China Drug Regulatory Reforms | NMPA Updates

China’s pharmaceutical Regulatory environment continues evolving rapidly as the National Medical Products Administration (NMPA) strengthens innovation-focused policies, accelerated approval pathways, lifecycle supervision, and compliance oversight. These reforms are reshaping how pharmaceutical and biotechnology companies approach product registration, market entry, pharmacovigilance, and...

Freyr Solutions

2026-06-30 13:07:12

China Pharma Market Entry & NMPA Approval Guide

China remains one of the most attractive pharmaceutical markets globally, but navigating China's pharmaceutical regulations requires strategic planning, Regulatory expertise, and strong compliance management. With evolving NMPA requirements, electronic submission standards, and accelerated review pathways, pharmaceutical companies must prepare carefully before entering the Chinese market. Here...

Freyr Solutions

2026-06-30 13:05:51

Mehr sehen